Publicaciones en las que colabora con José Manuel Cózar Olmo (18)

2021

  1. Tumor escape phenotype in bladder cancer is associated with loss of HLA class I expression, T-cell exclusion and stromal changes

    International Journal of Molecular Sciences, Vol. 22, Núm. 14

2019

  1. A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer

    Annals of Surgical Oncology, Vol. 26, Núm. 8, pp. 2631-2639

2016

  1. Frequent HLA class I alterations in human prostate cancer: molecular mechanisms and clinical relevance

    Cancer Immunology, Immunotherapy, Vol. 65, Núm. 1, pp. 47-59

2013

  1. VEGF polymorphisms are not associated with an increased risk of developing renal cell carcinoma in Spanish population

    Human Immunology, Vol. 74, Núm. 1, pp. 98-103

2012

  1. Association between C13ORF31, NOD2, RIPK2 and TLR10 polymorphisms and urothelial bladder cancer

    Human Immunology, Vol. 73, Núm. 6, pp. 668-672

2011

  1. Bacillus Calmette-Guerin immunotherapy of bladder cancer induces selection of human leukocyte antigen class I-deficient tumor cells

    International Journal of Cancer, Vol. 129, Núm. 4, pp. 839-846

2010

  1. Higher HLA class i expression in renal cell carcinoma than in autologous normal tissue

    Tissue Antigens, Vol. 75, Núm. 2, pp. 110-118

  2. Impact of interleukin-18 polymorphisms-607 and -137 on clinical characteristics of renal cell carcinoma patients

    Human Immunology, Vol. 71, Núm. 3, pp. 309-313

2009

  1. A polymorphism in the interleukin-10 promoter affects the course of disease in patients with clear-cell renal carcinoma

    Human Immunology, Vol. 70, Núm. 1, pp. 60-64

2008

  1. Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer

    BMC Cancer, Vol. 8

  2. Late pulmonary metastases of renal cell carcinoma immediately after post-transplantation immunosuppressive treatment: A case report

    Journal of Medical Case Reports, Vol. 2

2007

  1. High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer

    Human Immunology, Vol. 68, Núm. 8, pp. 698-704

2006

  1. Analysis of the expression of HLA class I, proinflammatory cytokines and chemokines in primary tumors from patients with localized and metastatic renal cell carcinoma

    Tissue Antigens, Vol. 68, Núm. 4, pp. 303-310

  2. LOH at 6p21.3 region and HLA class altered phenotypes in bladder carcinomas

    Immunogenetics, Vol. 58, Núm. 7, pp. 503-510

2005

  1. Analysis of NK cells and chemokine receptors in tumor infiltrating CD4 T lymphocytes in human renal carcinomas

    Cancer Immunology, Immunotherapy, Vol. 54, Núm. 9, pp. 858-866

  2. Coordinated downregulation of the antigen presentation machinery and HLA class I/β2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer

    International Journal of Cancer, Vol. 113, Núm. 4, pp. 605-610

2003

  1. HLA class I expression in bladder carcinomas

    Tissue Antigens, Vol. 62, Núm. 4, pp. 324-327

2001

  1. A nucleotide insertion in exon 4 is responsible for the absence of expression of an HLA-a*0301 allele in a prostate carcinoma cell line

    Immunogenetics, Vol. 53, Núm. 7, pp. 606-610